BerGenBio to present updates from ongoing Phase II bemcentinib combination study in refractory NSCLC at WCLC 2020

Date: 29th January 2021

Time: 09.50 AM Singapore Time / 02.50 AM CET

Title: A phase II study of the oral selective AXL inhibitor bemcentinib with pembrolizumab in refractory patients with advanced NSCLC

Presenting Author: Dr. Matthew G. Krebs PhD.

Session/Abstract ID: Immunotherapy (Phase II/III Trials) # 3647

The presentation can be found at www.bergenbio.com under Investors / Presentations